NCT05285982: An ongoing trial by Boehringer Ingelheim
This trial is ongoing. It must report results 10 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05285982 |
|---|---|
| Title | An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 3 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease (InPedILD®-ON) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 6, 2022 |
| Completion date | July 14, 2025 |
| Required reporting date | July 14, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |